1346747-14-5

Usage

Uses

Used in Pharmaceutical Industry:
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, relis used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a promising candidate for the development of new drugs with potential applications in treating various diseases.
Used in Antimicrobial Applications:
In the pharmaceutical industry, 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, relis used as a building block for the development of antimicrobial agents. Its structure can be modified to create new compounds with enhanced activity against various pathogens, including bacteria, fungi, and parasites.
Used in Anticancer Applications:
The compound may also be used in the development of anticancer drugs due to its potential to interact with cellular targets and disrupt cancer cell growth. Its unique structure and functional groups can be exploited to design new molecules with improved efficacy and selectivity against cancer cells.
Used in Drug Delivery Systems:
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, relcan be utilized in the design of drug delivery systems to improve the bioavailability and targeting of therapeutic agents. Its structural features can be incorporated into nanoparticles or other carriers to enhance the delivery of drugs to specific cells or tissues, potentially improving the efficacy and reducing side effects.

Upstream product

• 112811-72-0 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 
• 151213-40-0 (1S,6S)-2,8-diazabicyclo[4.3.0]nonane 
• 496919-99-4 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline-carboxylic acid O₃,O₄-bis(propyloxy-O)borate 
• 186826-86-8 moxifloxacin hydrochloride 
• 1028205-69-7 C₂₅H₃₃FN₄O₃ 
• 1028205-70-0 C₃₂H₃₇FN₄O₅ 
• 1028205-71-1 C₃₀H₄₁FN₄O₅ 
• 1028205-72-2 C₂₁H₂₅FN₄O₃ 
• 112811-70-8 ethyl 3-(cyclopropylamino)-2-(2,4,5-trifluoro-3-methoxybenzoyl)acrylate 
• 128740-14-7 8-benzyl-2,8-diazabicyclo[4.3.0]nonane 
• 151213-42-2 [R,R]-2,8-diazabicyclo[4.3.0]nonane 

Downstream Products

• 721970-35-0 methyl 1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 721970-37-2 N-methylmoxifloxacin 
• 172426-88-9 7-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid 
• 721970-36-1 1-cyclopropyl-7-{(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl}-6-fluoro-8-hydroxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid 
• 1029364-75-7 1-cyclopropyl-8-ethoxy-6-fluoro-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4 oxo-1,4-dihydroquinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Fluorescence quenching study of moxifloxacin interaction with calf thymus DNA

Moxi oxacin (MOX) is a fourth-generation synthetic uoroquinolone antibacterial agent with many important therapeutic properties. Fluorescence quenching was used to study the interaction of MOX with calf thymus DNA (ct- DNA) in aqueous solution. The intercalative binding mode and a static quenching mechanism were conflrmed by the Stern-Volmer quenching rate constant (Kq) of 3.48 × 1011 M-1 s-1 at 298 K. The thermodynamic parameters (δH = -118.4 KJ mol-1 and δS = -299.4 J mol-1 K-1) were calculated at different temperatures, and they indicate that the main forces between MOX and ct-DNA are hydrogen bonding and Van der Waals force. We proved at the same time the presence of one single binding site on ct-DNA, and the binding constant is 1.28 × 105 M-1 at physiological pH. The results may provide a basis for further studies and clinical application of antibiotics drugs. Tubitak.

Preparation method of moxifloxacin

The invention provides a preparation method of moxifloxacin, which comprises the following steps: taking 1-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-1, 4-dihydro-3-quinolinecarboxylic acid and (S, S)-2, 8-diazabicyclo[4.3. 0] nonane as raw materials, in an organic solvent, in the presence of an acid-binding agent, and carrying out condensation reaction by taking the tri-coordinated boride cation-chloroaluminate ionic liquid as a catalyst to prepare moxifloxacin. The structural formula of the tri-coordinated boride cation-chloroaluminate ionic liquid is BX2L, X is a halogen atom, and L is selected from 4-picoline (4-pic), imidazole (mim) and dimethylacetamide (DMA) ligands. The preparation method of moxifloxacin has the advantages of simple reaction steps, high yield, high product purity, mild conditions and easiness in industrial production.

Nano-Fe3 O4@ZrO2-SO3 H as highly efficient recyclable catalyst for the green synthesis of fluoroquinolones

Nano-Fe3 O4 @ZrO2-SO3 H (n-FZSA), was utilized as a magnetic catalyst for the synthesis of various fluoroquinolone compounds. These compounds were prepared by the direct amination of 7-halo-6-fluoroquinolone-3-carboxylic acids with piperazine derivatives and (4aR,7aR)-octahydro-1H-pyrrolo[3,4-b] pyridine in water. The results showed that n-FZSA exhibited high catalytic activity towards the synthesis of fluoroquinolone derivatives, giving the desired products in high yields. Furthermore, the catalyst was recyclable and could be used at least seven times without any discernible loss in its catalytic activity. Overall, this new catalytic method for the synthesis of fluoroquinolone derivatives provides rapid access to the desired compounds in refluxing water following a simple work-up procedure, and avoids the use of organic solvents.

Conventional and microwave-assisted synthesis of quinolone carboxylic acid derivatives

Various antibacterial fluoroquinolone compounds are synthesized by the direct amination of 7-halo-6-fluoroquinolone-3-carboxylic acids with a variety of piperazine derivatives and (4aR,7aR)-octahydro-1H-pyrrolo[3,4-b]pyridine using microwave under different reaction conditions. Solvent free high yield microwave synthesis of antibacterial fluoroquinolone compounds is convenient, rapid and environmentally friendly method.

IR, FT-ICR-MS studies on (1′S, 6′S)-1-cyclopropyl-7-(2,8- diazabicyclo[4.3.0] non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3- carboxylic acid hydrochloride salt

The infrared spectra of (1′S, 6′S)-1-cyclopropyl-7-(2,8- diazabicyclo[4.3.0] non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3- carboxylic acid hydrochloride salt (CLF-HCl) were studied and compared with free base. Their fragmentation pathways were investigated using tandem mass spectrometric (MS/MS) techniques on Fourier-transform ion cyclotron resonance spectrum, and many characteristic fragment ions were found.

Process for the preparation of moxifloxacin hydrochloride and intermediates thereof

The present invention refers to a process for the preparation of Moxifloxacin hydrochloride through the synthesis of Moxifloxacin salts with sulfonic acids.

MOXIFLOXACIN HYDROCHLORIDE COMPOUNDS AND INTERMEDIATES AND METHODS FOR MAKING SAME

Methods for producing moxifloxacin hydrochloride compounds having very low levels of impurities are provided. Compounds produced using such methods and pharmaceutical compositions including such compounds are also provided.

Process for the Synthesis of Moxifloxacin Hydrochloride

A new polymorph of moxifloxacin hydrochloride is described, together with a method for making the polymorph. In addition, new intermediates in the formation of moxifloxacin hydrochloride are described, having formulas (1) and (II):

IMPROVED PROCESS FOR THE PREPARATION OF (S.S)-2.8-DIAZABICYCLO[4.3.0]NONANE

The present invention is directed to an improved industrially viable, cost effective process for manufacturing (S,S)-2,8-Diazabicyclo[4.3.0]nonane in a substantially pure form and consequent conversion to Moxifloxacin hydrochloride monohydrate.

CRYSTALLINE FORM OF MOXIFLOXACIN BASE

The present invention relates to a crystalline form of moxifloxacin base, to a process for its preparation, to pharmaceutical compositions containing it, and to its use as an antibacterial agent.